GlassScriptPhysician profile
Tarita Thomas
NPI 1659572014
$8,306.38
in general payments reported to CMS, 2019-2025
7 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $5,215 · 2023: $145 · 2024: $2,550 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,888 · Food and Beverage: $1,002 · Travel and Lodging: $12.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,887.50 |
| Food and Beverage | $1,002.48 |
| Travel and Lodging | $12.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viewray Technologies INC | $5,215.17 | 2022 | |
| Servier Pharmaceuticals LLC | $1,967.89 | 2024 | |
| Elekta, INC. | $526.38 | 2023-2024 | Elekta Medical Linear Accelerator |
| Novocure INC. | $305.01 | 2024-2025 | Optune Gio, Optune |
| Tactile Systems Technology INC | $145.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $111.91 | 2021-2024 | Tagrisso |
| Siemens Medical Solutions USA, INC. | $35.01 | 2025 | Eclipse Treatment Planning System For External Beam Radiation Therapy, Truebeam, Vitalbeam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarita Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.